T-E Meds provides complementary technologies with CHO Pharma to form a robust ADC development platform
Website link: https://news.gbimonthly.com/tw/article/show.php?num=61824&range=news
【Reported by Taiwan Global Bio Monthly】The president – Dr. Tse-Wen Chang presents the Immunwork’s latest progress in the 40th anniversary activities of Development Center for Biotechnology (DCB)
Website link: https://news.gbimonthly.com/tw/article/show.php?num=60662&utm_source=dable
Immunwork’s latest research result is published in J. Med. Chem.
Exciting News! Immunwork’s Latest Published Paper Offers Promising Solutions for Pancreatic Cancer Treatment, Diagnostics, and Applications in ADC and ARC! We are thrilled to announce the publication of our paper, “Site-specific Conjugation of 6 DOTA Chelators to a CA19-9-targeting scFv-Fc Antibody for Imaging and Therapy,” in the prestigious Journal of Medicinal Chemistry. Led by Dr.
Immunwork’s latest research result is published in J. Med. Chem. Read More »
Immunwork will present at BIO Asia-Taiwan conference
Immunwork is thrilled to announce its participation in the upcoming BIO Asia-Taiwan conference. Join us on July 28th as Dr. Kun-Po Li delivers a captivating company presentation.
Immunwork will present at BIO Asia-Taiwan conference Read More »
【Reported by Taiwan Global Bio Monthly】Immunwork link future to T-E Meds, promoting ADC, ARC platforms development
Reported link: https://news.gbimonthly.com/tw/audiovisual/show.php?num=59755
BIO 2023 International Convention in Boston
T-E Meds has been selected as a finalist for the Start-up Stadium picking competition in the BIO international convention. T-E Meds stand out through its innovative “Multi-Arm Linker” technology platform. This technology can be utalized to design and create novel ADC/ARC drugs to improve the efficacy and safety. T-E Meds was also selected as an
BIO 2023 International Convention in Boston Read More »
Immunwork to present at the 2nd Next-Generation Conjugates Summit in Boston
Dr. Hsing-Mao Chu, VP of R&D at Immunwork is speaking at the 2nd Next-Generation Conjugates Summit in Boston next week. Dr. Chu will introduce our innovative antibody-radionuclide conjugate (ARC) technology platform and its application in pancreatic cancer diagnosis/treatment.Join us at this exciting conference!
Immunwork to present at the 2nd Next-Generation Conjugates Summit in Boston Read More »
Immunwork to present at Biotech Showcase™ 2023 – updates in proprietary ADC / ARC technology platforms and fundraising plan
Immunwork, Inc., today announced that it is presenting at Biotech Showcase™ 2023. This year, registered attendees can view Immunwork’s presentation live, and also access a recorded version. With 24×7 on-demand access, attendees can view recorded presentations at their convenience when scheduling does not allow viewing during the main event week. Dr. Kun-Po Li, Manager of
【Reported by Economic Daily】Immunwork’s novel drugs challenge incurable diseases
Reported link: https://www.immunwork.com/include/download.php?dl=MjAyMTAwNDI0X158ZmlsZXNhcHBlbmRzXnwwMDAwMDAwMDAx
【Reported by Economic Daily】Immunwork’s novel drugs challenge incurable diseases Read More »
Invited lectures on November 15th, 2022 Antibody Therapeutic Conference – Extended Application of Antibody
Reported link: https://news.gbimonthly.com/tw/article/show.php?num=54517&kind=1